So now the concerns resurface over Jason's LymPro revenue figures, and how Gerald needs to address it. Why am I not surprised? A couple of days of confidence is too much to deal with, I suppose. And by all means let's stir up the dilution concerns once again. Maybe JP can jump in here too.

Now that you're returned to business as usual with the "critical thinking" and the "valid shareholder concerns", welcome back to ignore.